Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.
Department of Cardiology, Barts Heart Centre, St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.
Cytotherapy. 2019 Oct;21(10):1007-1018. doi: 10.1016/j.jcyt.2019.04.056. Epub 2019 Sep 17.
The human umbilical cord has recently emerged as an attractive potential source of mesenchymal stromal cells (MSCs) to be adopted for use in regenerative medicine. Umbilical cord MSCs (UC-MSCs) not only share the same features of all MSCs such as multi-lineage differentiation, paracrine functions and immunomodulatory properties, they also have additional advantages, such as no need for bone marrow aspiration and higher self-renewal capacities. They can be isolated from various compartments of the umbilical cord (UC) and can be used for autologous or allogeneic purposes. In the past decade, they have been adopted in cardiovascular disease and have shown promising results mainly due to their pro-angiogenic and anti-inflammatory properties. This review offers an overview of the biological properties of UC-MSCs describing available pre-clinical and clinical data with respect to their potential therapeutic use in cardiovascular regeneration, with current challenges and future directions discussed.
最近，人类脐带已成为间充质基质细胞（MSCs）的有吸引力的潜在来源，可用于再生医学。脐带间充质干细胞（UC-MSCs）不仅具有所有 MSCs 的相同特征，如多能分化、旁分泌功能和免疫调节特性，它们还有一些额外的优势，例如不需要骨髓抽吸和更高的自我更新能力。它们可以从脐带的不同部位分离出来，并可用于自体或同种异体。在过去的十年中，它们已被用于心血管疾病，并取得了有希望的结果，主要是由于它们的促血管生成和抗炎特性。本综述概述了 UC-MSCs 的生物学特性，描述了其在心血管再生方面潜在治疗用途的临床前和临床数据，讨论了当前的挑战和未来的方向。
